Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
Is the Options Market Predicting a Spike in Puma Biotechnology Stock?
10:15am, Monday, 21'st Apr 2025
Investors need to pay close attention to PBYI stock based on the movements in the options market lately.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Wednesday, 02'nd Apr 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that inducement awards were granted to staff hired in March, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Puma SE: Undervalued With Tailwinds Ahead
04:53am, Monday, 31'st Mar 2025
Puma SE is poised for a turnaround with strong growth plans in the US market and strategic athlete endorsements, leading me to assign a "Buy" recommendation. Despite recent subpar financial performanc
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
09:00am, Wednesday, 26'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will present clinical data on its drug neratinib in a poster presentation on April 28 at the 2025 AACR Annual Meeting.
PUMA SE: This Is The Right Time To Buy
07:46am, Friday, 21'st Mar 2025
Puma SE's stock has dropped nearly 50% year-to-date, with an additional 20% decline following its Q4 earnings, creating a potential value opportunity for long-term investors. Despite consistent revenu
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06:05pm, Wednesday, 05'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved th
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
05:30pm, Wednesday, 05'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
04:11pm, Wednesday, 05'th Mar 2025
LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach will provide an overview of Puma Biotechnology at the Barclays Annual Global Healthcare Conference at 2:00 p.m. ET on March 11.
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
10:46am, Monday, 03'rd Mar 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
10:46am, Friday, 28'th Feb 2025
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript
09:02pm, Thursday, 27'th Feb 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Pr
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
07:25pm, Thursday, 27'th Feb 2025
Puma Biotech (PBYI) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.31 per share a year ago.
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Thursday, 27'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and FY-2024 earnings results after the close on Feb. 27 and follow with a conference call to discuss results.
Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference
04:15pm, Wednesday, 26'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will prov
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
04:15pm, Thursday, 13'th Feb 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 4Q and full year 2024 results on Feb. 27 and follow with a conference call at 1:30 p.m. PT/4:30 p.m. ET.
